Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The macrophage activation marker soluble CD163 is elevated and associated with liver disease phenotype in patients with Wilson's disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Clinical impact of endoscopic ultrasound-guided through-the-needle microbiopsy in patients with pancreatic cysts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reply to Firkins and Krishna

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Emilie Glavind
  • Daniel N Gotthardt
  • Jan Pfeiffenberger
  • Thomas Damgaard Sandahl
  • Teodora Bashlekova
  • Gro Linno Willemoe
  • Jane Preuss Hasselby
  • Karl Heinz Weiss
  • Holger Jon Møller
  • Hendrik Vilstrup
  • William M Lee
  • Michael L Schilsky
  • Peter Ott
  • Henning Grønbæk
Vis graf over relationer

BACKGROUND: Macrophages play a significant role in liver disease development and progression. The macrophage activation marker soluble (s)CD163 is associated with severity and prognosis in a number of different acute and chronic liver diseases but has been only sparsely examined in Wilson's disease (WD). We investigated sCD163 levels in patients with acute and chronic WD and hypothesized associations with liver disease phenotype and biochemical markers of liver injury.

METHODS: We investigated sCD163 in two independent cohorts of WD patients: 28 patients with fulminant WD from the US Acute Liver Failure (ALF) Study Group registry and 147 patients with chronic disease from a German WD registry. We included a control group of 19 healthy individuals. Serum sCD163 levels were measured by ELISA. Liver CD163 expression was determined by immunohistochemistry.

RESULTS: In the ALF cohort, median sCD163 was 10-fold higher than in healthy controls (14.6(2.5-30.9) vs. 1.5(1.0-2.7) mg/L, p < 0.001). In the chronic cohort, median sCD163 was 2.6(0.9-24.9) mg/L. There was no difference in sCD163 according to subgroups based on initial clinical presentation, i.e. asymptomatic, neurologic, hepatic, or mixed. Patients with cirrhosis at the time of diagnosis had higher sCD163 compared with those without cirrhosis (3.0(1.2-24.9) vs. 2.3(0.9-8.0) mg/L, p < 0.001); and both cohorts significantly lower than the ALF patients. Further, sCD163 correlated positively with ALT, AST, GGT and INR (rho = 0.27-0.53); and negatively with albumin (rho = - 0.37), (p ≤ 0.001, all). We observed immunohistochemical CD163 expression in liver tissue from ALF patients.

CONCLUSIONS: Although sCD163 is not specific for WD, it was elevated in WD patients, especially in those with ALF. Further, sCD163 was higher in patients with cirrhosis compared to patients without cirrhosis and associated with biochemical markers of liver injury and hepatocellular function. Thus, macrophage activation is evident in WD and associates with liver disease phenotype and biochemical parameters of liver disease. Our findings suggest that sCD163 may be used as a marker of liver disease severity in WD patients.

OriginalsprogEngelsk
TidsskriftOrphanet Journal of Rare Diseases
Vol/bind15
Udgave nummer1
Sider (fra-til)173
ISSN1750-1172
DOI
StatusUdgivet - 2 jul. 2020

ID: 61629079